Caspase-2 and tau-a toxic partnership?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Apoptotic cell death in disease-Current understanding of the NCCD 2023.Cell death and differentiation · 2023
   Review
2. Targeting caspase-2 interactions with tau in Alzheimer's disease and related dementias.Translational research : the journal of laboratory and clinical medicine · 2023
   Review
3. Characterization of caspase-2 inhibitors based on specific sites of caspase-2-mediated proteolysis.Archiv der Pharmazie · 2022
   Article
4. Structure-Based Design and Biological Evaluation of Novel Caspase-2 Inhibitors Based on the Peptide AcVDVAD-CHO and the Caspase-2-Mediated Tau Cleavage Sequence YKPVD314.ACS pharmacology & translational science · 2022
   Article
5. A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington's disease patients.Acta neuropathologica communications · 2019
   Article

Corrections and comments

• Comment on
  Caspase-2 cleavage of tau reversibly impairs memory.2016

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as